- Home
- DCOM vs ARVN Comparison
DCOM vs ARVN Comparison
Compare DCOM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- ARVN
- Stock Information
- Founded
- DCOM 1864
- ARVN 2015
- Country
- DCOM United States
- ARVN United States
- Employees
- DCOM N/A
- ARVN N/A
- Industry
- DCOM Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- ARVN Health Care
- Exchange
- DCOM Nasdaq
- ARVN Nasdaq
- Market Cap
- DCOM 1.6B
- ARVN 1.8B
- IPO Year
- DCOM 1996
- ARVN 2018
- Fundamental
- Price
- DCOM $33.96
- ARVN $19.10
- Analyst Decision
- DCOM Buy
- ARVN Strong Buy
- Analyst Count
- DCOM 6
- ARVN 13
- Target Price
- DCOM $33.50
- ARVN $63.00
- AVG Volume (30 Days)
- DCOM 285.2K
- ARVN 855.2K
- Earning Date
- DCOM 01-24-2025
- ARVN 10-30-2024
- Dividend Yield
- DCOM 2.95%
- ARVN N/A
- EPS Growth
- DCOM N/A
- ARVN N/A
- EPS
- DCOM 1.50
- ARVN N/A
- Revenue
- DCOM $313,737,000.00
- ARVN $161,100,000.00
- Revenue This Year
- DCOM N/A
- ARVN $237.44
- Revenue Next Year
- DCOM $29.45
- ARVN N/A
- P/E Ratio
- DCOM $22.59
- ARVN N/A
- Revenue Growth
- DCOM N/A
- ARVN 1.07
- 52 Week Low
- DCOM $17.29
- ARVN $18.51
- 52 Week High
- DCOM $37.60
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- DCOM 46.61
- ARVN 32.23
- Support Level
- DCOM $33.48
- ARVN $18.51
- Resistance Level
- DCOM $35.79
- ARVN $26.78
- Average True Range (ATR)
- DCOM 1.14
- ARVN 1.66
- MACD
- DCOM -0.40
- ARVN -0.67
- Stochastic Oscillator
- DCOM 13.15
- ARVN 6.95
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.